FY2024 Earnings Estimate for CRSP Issued By Chardan Capital

CRISPR Therapeutics AG (NASDAQ:CRSP) – Investment analysts at Chardan Capital upped their FY2024 earnings per share (EPS) estimates for shares of CRISPR Therapeutics in a research note issued on Wednesday, November 6th. Chardan Capital analyst Y. Livshits now forecasts that the company will post earnings per share of ($4.84) for the year, up from their previous forecast of ($5.75). Chardan Capital has a “Buy” rating and a $94.00 price objective on the stock. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.23) per share. Chardan Capital also issued estimates for CRISPR Therapeutics’ FY2025 earnings at ($4.62) EPS.

A number of other equities research analysts also recently issued reports on CRSP. Stifel Nicolaus decreased their price objective on CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating on the stock in a research report on Tuesday, August 6th. Royal Bank of Canada restated a “sector perform” rating and issued a $53.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Rodman & Renshaw assumed coverage on shares of CRISPR Therapeutics in a research report on Friday, August 2nd. They set a “buy” rating and a $90.00 price objective on the stock. Truist Financial lowered their target price on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a report on Monday, August 12th. Finally, Barclays cut their price target on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a report on Wednesday, November 6th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $74.94.

CRISPR Therapeutics Trading Down 7.5 %

Shares of NASDAQ CRSP opened at $50.73 on Monday. CRISPR Therapeutics has a 12-month low of $43.42 and a 12-month high of $91.10. The firm’s 50-day moving average price is $47.70 and its 200-day moving average price is $52.14. The stock has a market capitalization of $4.33 billion, a price-to-earnings ratio of -17.93 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, topping the consensus estimate of ($1.42) by $0.41. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. The company had revenue of $0.60 million for the quarter, compared to analysts’ expectations of $6.65 million. During the same quarter in the previous year, the business posted ($1.41) earnings per share.

Institutional Investors Weigh In On CRISPR Therapeutics

Hedge funds have recently made changes to their positions in the stock. Global Trust Asset Management LLC raised its holdings in CRISPR Therapeutics by 150.0% in the second quarter. Global Trust Asset Management LLC now owns 500 shares of the company’s stock worth $27,000 after purchasing an additional 300 shares in the last quarter. Larson Financial Group LLC raised its stake in shares of CRISPR Therapeutics by 95.5% during the 2nd quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock worth $31,000 after acquiring an additional 276 shares in the last quarter. GPS Wealth Strategies Group LLC lifted its position in CRISPR Therapeutics by 99.7% during the second quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock valued at $33,000 after acquiring an additional 307 shares during the last quarter. Itau Unibanco Holding S.A. acquired a new stake in CRISPR Therapeutics in the second quarter valued at approximately $35,000. Finally, Darwin Wealth Management LLC purchased a new position in CRISPR Therapeutics in the third quarter worth $43,000. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at CRISPR Therapeutics

In other news, General Counsel James R. Kasinger sold 1,089 shares of the firm’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $50,398.92. Following the transaction, the general counsel now owns 62,597 shares in the company, valued at approximately $2,896,989.16. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 4,293 shares of the company’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $198,680.04. Following the completion of the sale, the chief executive officer now owns 226,540 shares in the company, valued at $10,484,271.20. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel James R. Kasinger sold 1,089 shares of the stock in a transaction on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $50,398.92. Following the sale, the general counsel now directly owns 62,597 shares in the company, valued at $2,896,989.16. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 4.10% of the stock is currently owned by corporate insiders.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.